Gram-Negative, Non-Lactose-Fermenting, Oxidase-Positive Bacteria
The most likely organism is Pseudomonas aeruginosa, which is the most clinically significant gram-negative, non-lactose-fermenting, oxidase-positive bacterium encountered in healthcare settings.
Primary Identification
P. aeruginosa is the predominant pathogen fitting these characteristics and represents the most common multidrug-resistant gram-negative bacterial pathogen causing hospital-acquired infections 1. This organism:
- Is oxidase-positive
- Does not ferment lactose
- Gram-negative rod
- Often produces characteristic pigments (pyocyanin, pyoverdin), though 8.3% are non-pigmented and 21.2% show delayed pigmentation 2
Other Differential Organisms
While P. aeruginosa is most likely, other oxidase-positive, non-lactose-fermenting gram-negative bacteria include:
Less common but clinically relevant:
- Pseudomonas alcaligenes (11 strains identified in one series) 2
- Pseudomonas cepacia (now Burkholderia cepacia) - particularly in cystic fibrosis patients 3
- Stenotrophomonas maltophilia - though this is actually oxidase-variable 3
- Achromobacter xylosoxidans - multidrug-resistant with intrinsic resistance to many agents 4
- Aeromonas species - found in aquatic environments and food 5
- Shewanella species - produces hydrogen sulfide, previously misidentified as Pseudomonas 6
- Alcaligenes and Achromobacter species 3
Clinical Significance
The identification matters critically for treatment decisions. P. aeruginosa infections require specific antipseudomonal coverage with agents such as 1:
- Piperacillin-tazobactam 4.5 g IV q6h
- Cefepime or ceftazidime 2 g IV q8h
- Carbapenems (imipenem 500 mg IV q6h or meropenem 1 g IV q8h)
- Fluoroquinolones (ciprofloxacin 400 mg IV q8h or levofloxacin 750 mg IV daily)
- Aminoglycosides (though not as monotherapy)
- Aztreonam 2 g IV q8h
For high-risk patients or those with prior antibiotic exposure within 90 days, dual antipseudomonal coverage from different classes is recommended 1.
Resistance Patterns
P. aeruginosa has intrinsic resistance to many antimicrobials mediated by multiple efflux pumps and can develop resistance to piperacillin, ceftazidime, cefepime, carbapenems, aminoglycosides, and fluoroquinolones 7. Some multidrug-resistant isolates are susceptible only to polymyxin B 7.
Key Diagnostic Pitfall
Do not assume all oxidase-positive, non-lactose fermenters are Pseudomonas. Definitive identification requires additional biochemical testing including glucose oxidation, gelatin liquefaction, growth at 42°C, and pigment production 2. Hydrogen sulfide production suggests Shewanella rather than Pseudomonas 6.
The clinical context (hospital-acquired pneumonia, ventilator-associated infection, structural lung disease, immunocompromised state) strongly supports P. aeruginosa as the most likely pathogen requiring immediate empiric antipseudomonal therapy while awaiting definitive identification and susceptibility testing 1.